Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 23, 2026

Eos Energy Announces Expiration and Results of Rights Offering

View original at globenewswire.com
Eos Energy Announces Expiration and Results of Rights Offering PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • As of the Expiration Date, the Company received subscriptions for 6,885,218 Units offered in the rights offering, based on tabulation by Broadridge.

    60% confidence

  • Approximately $263 million in gross proceeds have been raised in support of Frontier Power USA, exceeding the Company's original target, and is expected to initially support more than $1 billion of deployable project capital.

    60% confidence

  • The Subscription Agent is expected to distribute the shares, warrants, and sale proceeds on or about August 3, 2026.

    60% confidence

  • The Company has applied to list its Warrants on the Nasdaq Capital Market under the symbol EOSEW, but no assurance can be given the application will be approved.

    60% confidence

  • The Company expects to receive aggregate gross proceeds from the rights offering of $37.7 million.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com